Finerenone

SAN DIEGO — Compared with placebo, finerenone was associated with reductions in albuminuria and decreased risk of new-onset albuminuria among adults with heart failure, according to data from the FINEARTS-HF trial.

New data from the FINEARTS-HF trial show that finerenone improved outcomes in patients with HF compared with placebo across the entire midrange and preserved ejection fraction ranges.

In patients with HF and ejection fraction 40% or greater, the absolute risk reduction for total worsening HF events and CV death with finerenone vs. placebo was greatest in those with recent worsening HF, new data from FINEARTS-HF show.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

A single combined measurement of three modifiable biomarkers can predict future cardiovascular events when measured in healthy women at midlife, according to research presented at the European Society of Cardiology Congress.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.

Few areas in cardiology are as active as development and implementation of medical therapies for heart failure, and few people are as familiar with that landscape as Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC.

Adults with type 2 diabetes and chronic kidney disease derive similar cardiovascular and kidney benefits from finerenone, regardless of their level of insulin resistance, according to findings published in Diabetes Care.

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, may improve CV risk among patients with type 2 diabetes and kidney disease and those with albuminuria, according to a FIDELITY substudy published in JAMA Cardiology.